SAB Biotherapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
SAB Biotherapeutics, Inc. (SABS)
Company Research
Source: Yahoo! Finance
US$7.64 loss per share (further deteriorated from US$4.31 loss in FY 2022). All figures shown in the chart above are for the trailing 12 month (TTM) period SAB Biotherapeutics Revenues Beat Expectations, EPS Falls Short Revenue exceeded analyst estimates by 100%. Earnings per share (EPS) missed analyst estimates by 81%. Looking ahead, revenue is expected to decline by 103% p.a. on average during the next 2 years, while revenues in the Biotechs industry in the US are expected to grow by 18%. Performance of the American Biotechs industry. The company's shares are up 6.8% from a week ago. Risk Analysis Before we wrap up, we've discovered 5 warning signs for SAB Biotherapeutics (1 can't be ignored!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical
Show less
Read more
Impact Snapshot
Event Time:
SABS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SABS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SABS alerts
High impacting SAB Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SABS
News
- SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors [Yahoo! Finance]Yahoo! Finance
- SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of DirectorsGlobeNewswire
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.MarketBeat
- SAB Biotherapeutics, Inc. (NASDAQ: SABS) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $25.00 price target on the stock.MarketBeat
- SAB Biotherapeutics Provides SAB-142 Trial Update [Yahoo! Finance]Yahoo! Finance
SABS
Earnings
- 8/21/23 - Beat
SABS
Sec Filings
- 5/20/24 - Form 10-Q
- 5/15/24 - Form NT
- 5/14/24 - Form 3
- SABS's page on the SEC website